Suppression of lymphocyte mitogenesis by tamoxifen: Studies on protein kinase C, calmodulin and calcium

NeuroImmunoModulation

Volumn 7, Issue 2, 2000, Pages 68-76

  Baral, Edward ^a   Nagy, Eva ^a   Kwok, Siuchan ^a   McNicol, Archibald ^a   Gerrard, Jon ^b   Berczi, Istvan ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Ca2+; Lymphocyte proliferation; Tamoxifen

Indexed keywords

3,4,5 TRIMETHOXYBENZOIC ACID 8 (DIETHYLAMINO)OCTYL ESTER; CALCIMYCIN; CALCIUM ION; CALMIDAZOLIUM; CALMODULIN; CHLORPROMAZINE; EGTAZIC ACID; ESTROGEN RECEPTOR; LIPID A; MITOGENIC AGENT; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C; TAMOXIFEN; VERAPAMIL;

ANIMAL CELL; ARTICLE; B LYMPHOCYTE; BREAST CARCINOMA; CALCIUM TRANSPORT; CONTROLLED STUDY; DRUG MECHANISM; LYMPHOCYTE PROLIFERATION; MITOGENESIS; NONHUMAN; PRIORITY JOURNAL; RAT; SPLEEN CELL; T LYMPHOBLAST; T LYMPHOCYTE;

EID: 0034048915     PISSN: 10217401     EISSN: None     Source Type: Journal    
DOI: 10.1159/000026422     Document Type: Article

References (42)

1. Jordan CB: Metabolites of tamoxifen in animals and man. Identification, pharmacology and significance. Breast Cancer Res Treat 1982;2:123.
2. Stahl F, Schnorr D, Rohde W, Poppee I, Geier T, Dorner G: Effects of tamoxifen on the levels of luteinizing hormone (LH), follicle stimulating hormone (FSH), prolactin (PRL), 17-beta-oestradiol (E), total and free testosterone (T) and total and free dihydrotestosterone (DHT) in blood of patients with benign prostatic hyperplasia. Exp.Clin Endocrinol 1983;82:21-28.
3. Schwartz PE, MacLusky N, Naftolin F, Eisenfeld A: Tamoxifen-induced increase in cytosol progestin receptor levels in a case of metastatic endometrial cancer. Gynecol Oncol 1983;16: 41-48.
4. Baral E, Glas U, Rutquist L-E, Skoog L: Adjuvant therapy in postmenopausal patients with operative breast cancer, in Paterson A, Lees A (eds): Fundamental Problems in Breast Cancer. The Hague Nijhoff, 1987, p 235.
5. Baral E, Blomgren H, Rotstein S, Virving L: Anti-estrogen effects on human blood lymphocyte subpopulations in vitro. J Clin Lab Immunol 1985;17:33-35.
6. Baral E, Blomgren H, Wasserman J, Rotstein S, Von Stedingk L-V: Effect of tamoxifen on pokeweed mitogen-stimulated immunoglobulin secretion in vitro. J Clin Lab Immunol 1986;21:137-139.
7. Baral E, Vanky F: Effect of tamoxifen on cell-mediated autotumor lysis. J Clin Lab Immunol 1987;22:97-100.
8. Nagy E, Berczi I: Immunomodulation by tamoxifen and pergolide. Immunopharmacology 1986;12:145-153.
9. Baral E, Kwok S, Berczi I: Suppression of lymphocyte mitogenesis by tamoxifen. Immunopharmacology 1989;18:57-62.
10. Baral E, Kwok S, Berczi I: The influence of estradiol and tamoxifen on the mixed lymphocyte reaction in rats. Immunopharmacology 1991;21:191-198.
11. Baral E, Nagy E, Berczi I: Tamoxifen as an immunomodulatory agent; in Berczi I, Szelenyi J (eds): Advances in Psychoneuroimmunology. New York, Plenum Press, 1994, pp 233-241.
12. Baral E, Nagy E, Berczi I: Target cells are sensitized for cytotoxic T-lymphocyte-mediated destruction by estradiol and tamoxifen. Int J Cancer 1994;58:64-68.
13. Berczi I, Nagy E, Baral E: The amplification of cell-mediated cytolysis by estradiol and tamoxifen (abstract). 8th International Congress of Immunology, Budapest, 1992.
14. Baral E, Nagy E, Berczi I: Enhancement of natural killer cell mediated cytotoxicity by tamoxifen. Cancer 1995;75:591-599.
15. Su HD, Mazzei GJ, Vogler WR, Kuo JF: Effect of tamoxifen, a nonsteroidal antiestrogen, on phospholipid/calcium-dependent protein kinase and phosphorylation of its endogenous substrate proteins from the rat brain and ovary. Biochem Pharmacol 1985;34:3649-3653.
16. O'Brian CA, Liskamp RM, Solomon DH, Weinstein IB: Inhibition of protein kinase C by tamoxifen. Cancer Res 1985;45:2462-2465.
17. O'Brian CA, Housey GM, Weinstein IB: Specific and direct binding of protein kinase C to an immobilized tamoxifen analogue. Cancer Res 1988;48:3626-3629.
18. Lam HYP: Tamoxifen is a calmodulin antagonist in the activation of cAMP phosphodiesterase. Biochem Biophys Res Commun 1984;118: 27-32.
19. Valge VE, Wong JGP, Datlof BM, Sinskey AJ, Rao A: Protein kinase C is required for responses to T-cell receptor ligands but not to interleukin-2 in T cells. Cell 1988;55:101-112.
20. Gupta S, Gollapudi S, Vayuvegula B: Lipopolysaccharide-induced murinc B-cell proliferation: A role of protein kinase C. Cell Immunol 1988;117:425-429.
21. Crabtree GR: Contingent genetic regulatory events in T-lymphocyte activation. Science 1989;243:355-361.
22. + exchange and phospholipid turnover. Immunol Rev 1987;95:59-87.
23. Tanaka T, Shiu RPC, Gout PW, Beer CT, Noble RL, Friesen HG: A new sensitive and specific bioassay for lactogenic hormones: Measurement of prolactin and growth hormone in human scrum. J Clin Endocrinol 1980;51:1058-1063.
24. 3H]arachidonic acid and changes in cytosolic free calcium in fura-2-loaded human platelets stimulated by ionomycin and collagen. Biochem J 1986;235:869-877.
25. ++-transport ATPase and of calmodulin-regulated functions. Biochem Biophys Res Commun 1981;101:418-425.
26. Hait WN, DeRosa WT: Calmodulin as a target for new chemotherapeutic strategies. Cancer Invest 1988;6:499-511.
27. Matsumoto T, Takeshige K, Minakami S: Inhibition of phagocytotic metabolic changes of leukocytes by an intracellular calcium-antagonist 8-(N,N-dimethylamino)-octyl-3,4,5-trimethoxybenzoate. Biochem Biophys Res Commun 1979;88:974-979.
28. Biswas R, Vonderhaar BK: Antiestrogen inhibition of prolaction-induced growth of the Nb2 rat lymphoma cell line. Cancer Res 1989;49: 6295-6299.
29. López-Cabrera M, Santis AG, Fernández-Ruiz E, Blacher R, Esch F, Sánchez-Mateos P, Sánchez-Madrid F: Molecular cloning, expression, and chromosomal localization of the human earliest lymphocyte activation antigen AIM/ CD69, a new member of the C-type animal lectin superfamily of signal-transmitting receptors. J Exp Med 1993;178:537-547.
30. Berczi I, Nagy E: Hormones as immune modulating agents; in Krezina T (ed): Handbook of Immune Modulating Agents. New York, Dekker, 1997.
31. Nemere I, Norman AW: Steroid hormone actions at the plasma membrane: Induced calcium uptake and exocytotic events. Mol Cell Endocrinol 1991;80:C165-169.
32. Brandes LJ, LaBella FS: Histamine and calcium are independently regulated intracellular mediators of lymphocyte mitogencsis. Biochem Biophys Res Commun 1992;182:786-793.
33. Berczi I: The role of the growth and lactogenic hormone family in immune function. Neuroimmunomodulation 1994;1:201-216.
34. Berczi I, Baragar FD, Chalmers IM, Keystone EC, Nagy E, Warrington RJ: Hormones in self tolerance and autoimmunity: A role in the pathogenesis of rheumatoid arthritis? Autoimmunity 1993;16:45-56.
35. Berczi I: The influence of pituitary-adrenal axis on the immune system; in Berczi I (ed): Pituitary Function and Immunity. Boca Raton, CRC Press, 1986, pp 41-47.
36. Berczi I: Gonadotropins and sex hormones; in Berczi I (ed): Pituitary Function and Immunity. Boca Raton, CRC Press, 1986, pp 185-211.
37. Baral E, Nagy E, Berczi I: The effect of tamoxifen on the immune response; in Kellen JA (ed): Tamoxifen: Beyond the Antiestrogen. Boston, Blackwell Scientific Publishers, 1996, pp 137-178.
38. Mosselman S, Polman J, Dijkeme R: ER-beta: Identification and characterization of a novel human estrogen receptor. FEBS Lett 1996;392: 49-53.
39. Suda T, Takahashi T, Goldstein P, Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993;75:1169-1178.
40. Takahashi T, Tanaka M, Brannan CI, Jenkins NA, Copeland NG, Suda T, Nagata S: Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell 1994;76:969-976.
41. Ramsdell F, Seaman MS, Miller RE, Tough TW, Alderson MR, Lynch DH: gld/gld mice arc unable to express a functional ligand for Fas. Eur J Immunol 1994;24:928-933.
42. Arends MJ, Wyllie AH: Apoptosis: Mechanisms and roles in pathology. Int Rev Exp Pathol 1991;32:223-254.